Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
|Articles|May 13, 2015
Jeannie Woith on the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
Author(s)Jeannie Woith, BSN, RN, LMT
Jeannie Woith, BSN, RN, LMT, The James Cancer Hospital, The Ohio State University, discusses the treatment of oral mucositis in patients with head and neck cancer.
Advertisement
Jeannie Woith, BSN, RN, LMT, The James Cancer Hospital, The Ohio State University, discusses the treatment of oral mucositis in patients with head and neck cancer.
Advertisement
Related to this article
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.
The FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer that grew after chemotherapy and immunotherapy.
A woman with stage 4 pancreatic cancer shares how a once-daily RAS inhibitor changed her energy, routine and time with family.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
Advertisement
Advertisement